Experienced in Familial Dysautonomia

Dr. David S. Russell

New Haven, CT
Experienced
in Familial Dysautonomia
Specialties:Neurology
OverviewInsuranceLocationsClinical Research

Overview

David Russell is a Neurologist in New Haven, Connecticut. Dr. Russell and is rated as an Experienced provider by MediFind in the treatment of Familial Dysautonomia. His top areas of expertise are Progressive Supranuclear Palsy Atypical, Progressive Supranuclear Palsy, Supranuclear Ophthalmoplegia, and Parkinson's Disease.

His clinical research consists of co-authoring 36 peer reviewed articles and participating in 30 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Familial Dysautonomia.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CT
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

60 Temple St, Suite 8b, New Haven, CT 06510
203-401-4300

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials

Evaluation of [18F]APN-1607 as a PET Biomarker for Longitudinal Change in Tau Pathology in Participants With Progressive Supranuclear Palsy
Evaluation of [18F]APN-1607 as a PET Biomarker for Longitudinal Change in Tau Pathology in Participants With Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: February 20, 2025
Intervention Type: Drug
Study Phase: Phase 1
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™ (PPMI Early Imaging)
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™ (PPMI Early Imaging)
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2024
The Parkinson's Progression Markers Initiative (PPMI)
The Parkinson's Progression Markers Initiative (PPMI)
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: DaTscan
Study Phase: Phase 2
A Phase 2, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects
A Phase 2, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drug: 18F APN-1607
Study Phase: Phase 2
Assessment of Brain Tau Burden in Participants With Parkinson's Disease in the PPMI Study (PPMI Tau PET Imaging)
Assessment of Brain Tau Burden in Participants With Parkinson's Disease in the PPMI Study (PPMI Tau PET Imaging)
Enrollment Status: Completed
Publish Date: April 21, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Adaptive Design, Phase 1, Open-label Study to Investigate Receptor Occupancy in Brain After Single Oral Doses of LY3857210 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]-LY3818850 in Healthy Participants
An Adaptive Design, Phase 1, Open-label Study to Investigate Receptor Occupancy in Brain After Single Oral Doses of LY3857210 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]-LY3818850 in Healthy Participants
Enrollment Status: Completed
Publish Date: March 01, 2023
Intervention Type: Drug
Study Phase: Phase 1
The Dementia Symptom Management at Home Program: A Bundled Interprofessional Intervention to Improve Dementia Patient-Caregiver Dyad Quality of Care and Quality of Life Through Home Healthcare.
The Dementia Symptom Management at Home Program: A Bundled Interprofessional Intervention to Improve Dementia Patient-Caregiver Dyad Quality of Care and Quality of Life Through Home Healthcare.
Enrollment Status: Withdrawn
Publish Date: November 02, 2022
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase 1 Proof of Principle Study to Evaluate the Occupancy of A2A Receptors Using PET Radiotracer [18F]MNI-444 & Repeated Dosing of Oral Caffeine in Participants Without Parkinson's Disease Who Carry Pathogenic Mutation in the LRRK2 Gene
A Phase 1 Proof of Principle Study to Evaluate the Occupancy of A2A Receptors Using PET Radiotracer [18F]MNI-444 & Repeated Dosing of Oral Caffeine in Participants Without Parkinson's Disease Who Carry Pathogenic Mutation in the LRRK2 Gene
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Early Phase 1
Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Multiple Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LY3316612 in Healthy Subjects
Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Multiple Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LY3316612 in Healthy Subjects
Enrollment Status: Completed
Publish Date: November 04, 2020
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 1
Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Single Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LSN3316612 in Healthy Subjects
Assessment of Brain O-GlcNAcase (OGA) Enzyme Occupancy After Single Oral Doses of LY3372689 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]LSN3316612 in Healthy Subjects
Enrollment Status: Completed
Publish Date: April 22, 2020
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 1
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss in the Brain of Patients With Probable Alzheimer's Disease, Probable Parkinson's Disease (PD) Subjects as Compared to Healthy Volunteers (HV).
Enrollment Status: Completed
Publish Date: April 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Assessment of the Biodistribution and Safety of [18F]MNI-1054 in Healthy Subjects
Assessment of the Biodistribution and Safety of [18F]MNI-1054 in Healthy Subjects
Enrollment Status: Completed
Publish Date: May 23, 2019
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-1054 as a Marker for LSD1 in Healthy Subjects
An Open-label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-1054 as a Marker for LSD1 in Healthy Subjects
Enrollment Status: Completed
Publish Date: May 23, 2019
Intervention Type: Drug
Study Phase: Early Phase 1
An Open-Label Study To Evaluate D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562, Using Positron Emission Tomography (PET) With Ligand [18F]MNI-968 in Healthy Male Subjects
An Open-Label Study To Evaluate D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562, Using Positron Emission Tomography (PET) With Ligand [18F]MNI-968 in Healthy Male Subjects
Enrollment Status: Completed
Publish Date: April 22, 2019
Intervention Type: Drug
Study Phase: Early Phase 1
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects
Enrollment Status: Completed
Publish Date: October 22, 2018
Intervention Type: Drug
Study Phase: Phase 1
Assessment of the Biodistribution and Safety of [18F]MNI-968 (Aka PF-06730110) in Healthy Subjects
Assessment of the Biodistribution and Safety of [18F]MNI-968 (Aka PF-06730110) in Healthy Subjects
Enrollment Status: Completed
Publish Date: March 06, 2018
Intervention Type: Drug
Study Phase: Phase 1
An Open Label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
An Open Label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
Enrollment Status: Completed
Publish Date: March 06, 2018
Intervention Type: Drug
Study Phase: Early Phase 1
Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers
Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers
Enrollment Status: Completed
Publish Date: October 06, 2017
Intervention Type: Drug
Study Phase: Early Phase 1
Systemic Synuclein Sampling Study (S4)
Systemic Synuclein Sampling Study (S4)
Enrollment Status: Completed
Publish Date: August 17, 2017
Intervention Type: Drug, Procedure
Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions
Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions
Enrollment Status: Completed
Publish Date: January 06, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 27 Less Clinical Trials

36 Total Publications

Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study.
Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study.
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: January 22, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Roy N. Alcalay
Neurology
Expertise in
13
conditions
Dr. Roy N. Alcalay
Neurology
710 W 168th St, 
New York, NY 
 (61.7 mi)
212-305-5558
Languages Spoken:
English
See accepted insurances

Roy Alcalay is a Neurologist in New York, New York. Dr. Alcalay and is rated as an Elite provider by MediFind in the treatment of Familial Dysautonomia. His top areas of expertise are Parkinson's Disease, Striatonigral Degeneration Infantile, Gaucher Disease, Multiple System Atrophy, and Deep Brain Stimulation.

Expertise in
15
conditions
Dr. David M. Eidelberg
Neurology
Expertise in
15
conditions
Dr. David M. Eidelberg
Neurology
Department Of Neurology-movement Disorders Center, 865 Northern Boulevard, 
Great Neck, NY 
 (54.2 mi)
516-570-4477
Languages Spoken:
English
See accepted insurances

David Eidelberg is a Neurologist in Great Neck, New York. Dr. Eidelberg and is rated as a Distinguished provider by MediFind in the treatment of Familial Dysautonomia. His top areas of expertise are Parkinson's Disease, Cerebellar Multiple System Atrophy, Drug Induced Dyskinesia, Focal Dystonia, and Deep Brain Stimulation.

Expertise in
8
conditions
Dr. Matthew Imperioli
Neurology
Expertise in
8
conditions
Dr. Matthew Imperioli
Neurology

Nuvance Health Medical Practice Ct Inc

79 Sand Pit Rd, Suite 102, 
Danbury, CT 
 (27.1 mi)
203-749-5700
Languages Spoken:
English
See accepted insurances

Matthew Imperioli is a Neurologist in Danbury, Connecticut. Dr. Imperioli and is rated as an Advanced provider by MediFind in the treatment of Familial Dysautonomia. His top areas of expertise are Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Familial Dysautonomia, and Miller-Fisher Syndrome.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile